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Abstract
While aberrant cancer cell growth is frequently associated with altered biochemical metabolism, normal mitochondrial
functions are usually preserved and necessary for full malignant transformation. The transcription factor FoxO3A is a
key determinant of cancer cell homeostasis, playing a dual role in survival/death response to metabolic stress and
cancer therapeutics. We recently described a novel mitochondrial arm of the AMPK-FoxO3A axis in normal cells upon
nutrient shortage. Here, we show that in metabolically stressed cancer cells, FoxO3A is recruited to the mitochondria
through activation of MEK/ERK and AMPK, which phosphorylate serine 12 and 30, respectively, on FoxO3A N-terminal
domain. Subsequently, FoxO3A is imported and cleaved to reach mitochondrial DNA, where it activates expression of
the mitochondrial genome to support mitochondrial metabolism. Using FoxO3A−/− cancer cells generated with the
CRISPR/Cas9 genome editing system and reconstituted with FoxO3A mutants being impaired in their nuclear or
mitochondrial subcellular localization, we show that mitochondrial FoxO3A promotes survival in response to
metabolic stress. In cancer cells treated with chemotherapeutic agents, accumulation of FoxO3A into the
mitochondria promoted survival in a MEK/ERK-dependent manner, while mitochondrial FoxO3A was required for
apoptosis induction by metformin. Elucidation of FoxO3A mitochondrial vs. nuclear functions in cancer cell
homeostasis might help devise novel therapeutic strategies to selectively disable FoxO3A prosurvival activity.
Introduction
Carcinogenesis is a multistep process by which normal
cells evolve to a neoplastic state by acquiring a succession
of cancer hallmarks1. Tumor cell homeostasis is sustained
by the balance between these newly acquired oncogenic
features and pre-existing cellular functions. Paradigmatic
in this regard is the reprogramming of energy metabolism,
where normal cellular processes providing increased
energy production, macromolecular biosynthesis, and
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redox balance maintenance2–4 are ensured by the pre-
servation of key mitochondrial functions5–7.
Consistent with this view, proteins that have been
classically considered as tumor suppressors are sometimes
required to be functional for full malignant transforma-
tion. This is the case for FoxO3A, which can be both
friend and foe to cancer cells depending on the cellular
context8–10.
FoxO3A belongs to the FoxO (Forkhead-box O) family of
transcription factors, together with FoxO1, FoxO4 and
FoxO6, which are evolutionarily conserved from nema-
todes to mammals11. In mammals, FoxO3A functions are
mediated by the activation of a coordinated transcriptional
program involving genes that regulate cell cycle control,
cell death, cell metabolism, redox balance, DNA repair and
autophagy8. As all these genes share the conserved con-
sensus core recognition motif FHRE (5′TTGTTTAC3′)
within their DNA regulatory regions, expression specificity
is ensured by additional regulation mechanisms such as
phosphorylation-dependent subcellular localization,
whereby some kinases trigger FoxO3A nuclear exclusion
and subsequent cytoplasmic degradation (AKT and IKKß)
and others enable its nuclear localization and transcrip-
tional activation (p38 and AMPK)12–14. These enzymes
define the so-called “molecular FOXO code”, which is
critical for the fine-tuned regulation of FoxO factors’ dif-
ferent functions. FoxO3A has emerged as a major sensor
for metabolic stress and chemotherapeutic drug response
in cancer cells, playing a dual role at the crossroad between
survival and death. In metabolically stressed cancer cells,
activation of the FoxO3A-dependent transcriptional pro-
gram first leads to autophagy and cell cycle arrest as an
attempt to retain energy and increase ATP levels to survive,
but then triggers cell death under persistent stress condi-
tions15–17. Consistently, in cancer cells undergoing therapy-
induced genotoxic stress, FoxO3A is involved in
Fig. 1 FoxO3A accumulates into the mitochondria in metabolically stressed cell lines and normal tissues. a Immunogold labeling of HeLa
cells cultured in high glucose (HG) or switched to low glucose (LG, 0.75 mM glucose) for 24 h. Black dots represent gold particles recognizing FoxO3A
immunocomplexes. b, c Immunoblot analysis of mitochondria isolated from HCT116 cells upon b LG (24 h) and c 2-deoxy-glucose (2-DG) treatment
(1 mM, 6 h). Mitochondrial fractions were treated with proteinase K (PK) to degrade outer mitochondrial membrane proteins. PDH: loading control. d,
e Immunoblot analysis of mitochondrial fractions isolated from Caco2, HT29, SW-480 and HEK293 (d) and from NIH3T3 and MEF murine fibroblasts (e)
cultured in LG (24 h). Mitochondrial fractions were treated with PK alone or with PK and Triton X-100 to permeabilize mitochondria and degrade all
mitochondrial proteins. BCL2: outer membrane control; PDH: mitochondrial matrix control. f Immunoblot analysis of mitochondria-enriched fractions
isolated from murine kidney and liver and subjected to PK or combined PK and Triton X-100 treatment. PDH: mitochondrial matrix control. The
presented results are representative of at least three independent experiments
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detoxification and DNA repair thereby promoting survival,
while its pro-apoptotic function likely reflects an irrepar-
able level of damage18,19.
Recently, we reported that glucose restriction causes the
AMPK-dependent accumulation of FoxO3A into the
mitochondria of normal fibroblasts and muscle cells in
culture, followed by the formation of a transcriptional
complex containing FoxO3A, SIRT3 and the mitochon-
drial RNA polymerase (mtRNAPOL) at mitochondrial
DNA regulatory regions, thereby promoting expression of
the mitochondrial genome and a subsequent increase in
oxygen consumption. These results were confirmed
in vivo in tissues of fasting mice20, thus revealing a
mitochondrial arm of the AMPK-FoxO3A axis operating
as a recovery mechanism to sustain cellular metabolism
upon nutrient shortage and metabolic stress.
Here, we characterize this novel FoxO3A function in
cancer cells and provide compelling molecular evidence
that in metabolically stressed cancer cells and tumors
FoxO3A is recruited to the mitochondrial surface in a
MEK/ERK- and AMPK-dependent manner, while only
the MEK/ERK signal is required in cancer cells treated
with chemotherapeutic agents. After cleavage of its N-
terminal domain, FoxO3A is imported into the mito-
chondrial matrix where it activates a transcriptional pro-
gram leading to cancer cell survival. On the other hand,
mitochondrial FoxO3A (mtFoxO3A) is required for
apoptosis induction in cancer cells treated with
metformin.
Results
FoxO3A is cleaved at its N-terminus upon translocation
into the mitochondria of normal and cancer cells
In line with our previous findings in human and rodent
normal cells and tissues20, we detected FoxO3A into the
mitochondria of metabolically stressed HeLa cancer cells
(Fig. 1a).
To ascertain whether it could undergo post-
translational processing similar to other nuclear-
encoded mitochondrial proteins21, we purified mito-
chondria from several normal and cancer cell lines of
different origin cultured under high (HG) or low (LG)
glucose conditions and performed a proteinase K (PK)
protection assay to detect proteins localized at the outer
membrane or inside the mitochondria. In LG, anti-
FoxO3A antibodies revealed the presence of two bands in
the whole mitochondria fraction (at around 90 and 70
kDa), while after PK treatment only the 70 kDa band was
detected into the organelles (Fig. 1b, d, e and Supple-
mentary Figure S1b). These results indicate that anti-
FoxO3A antibodies recognized the full-length protein (90
kDa band) bound outside of the mitochondria, while
inside the organelle they detected a shorter 70 kDa form.
These findings were confirmed by treating cells with 2-
deoxy-glucose (2-DG) or iodoacetic acid (IA), two diverse
glycolysis inhibitors that induce metabolic stress (Fig. 1c
and Supplementary Figure S1a). Of note, a similar
migration pattern was observed in vivo when analyzing
mitochondria isolated from different mouse tissues
(Fig. 1f and Supplementary Figure S1c).
To our knowledge, this is the first report describing a
shorter form of FoxO3A and suggests that FoxO3A may
be processed similar to canonical mitochondrial proteins.
To rule out non-specific antibody binding, we transfected
a vector-expressing FoxO3A FLAG-tagged at the C-
terminal domain (Fig. 2a) in glucose-restricted HCT116
and HEK293 cells. Anti-FLAG antibodies revealed two
bands (90 and 70 kDa) corresponding to exogenous
FoxO3A in the purified mitochondrial fraction, while only
the 70 kDa band was detected after addition of PK
(Fig. 2b). Consistently, glucose-restricted HCT116 cells
transfected with a newly generated vector-expressing
FoxO3A tagged both at the N-terminus (with HA) and
at the C-terminus (with FLAG) showed the presence of
both signals (HA and FLAG) at 90 kDa in purified mito-
chondria, while only a 70 kDa band was detected by anti-
FLAG antibodies after PK treatment (Fig. 2c). Finally, we
deleted the entire N-terminus (aa 1–148) from FoxO3A-
FLAG and assessed its ability to localize at the mito-
chondria. Our data indicate that amino acids 1–148 are
required for FoxO3A localization at, and translocation
into the mitochondria (Fig. 2d).
(see figure on previous page)
Fig. 2 FoxO3A is cleaved at its N-terminus upon translocation into the mitochondria of normal and cancer cells. a Scheme of plasmids used.
b–e Cells were transfected with the indicated FoxO3A plasmids for 48 h; upon LG (0.75 mM glucose, 24 h), purified mitochondria were treated with
PK alone or with PK and Triton X-100. Total and mitochondrial proteins were analyzed by immunoblot. b HCT116 and HEK293 cells transfected with
FoxO3A-WT-FLAG. c HCT116 cells transfected with HA-FoxO3A-WT-FLAG. d HCT116 cells transfected with FoxO3A-WT-FLAG or FoxO3A-Δ1–148-
FLAG. e HCT116 cells transfected with FoxO3A-WT-FLAG or FoxO3A-Δ80-108-FLAG. β-actin and PDH were used as total lysate and mitochondria
controls, respectively. f Immunoblots performed with two different anti-FoxO3A antibodies in mitochondria isolated from HCT116 and HEK293 cells
cultured in LG (24 h). Mitochondrial fractions were subjected to PK treatment. β-actin and PDH were used as total lysate and mitochondrial fraction
controls, respectively. g HCT116 cells were transfected with control (siNC) or FoxO3A-specific siRNAs for 48 h and FoxO3A mitochondrial levels were
evaluated by immunoblot upon LG (24 h). PDH: loading control. fl. full-length FoxO3A, cl. cleaved FoxO3A, N-term. N-terminal domain, FKH-DBD
forkhead DNA-binding domain, NLS nuclear localization signal, TAD transactivation domain, C-term. C-terminal domain. The presented results are
representative of at least three independent experiments
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To further characterize FoxO3A N-terminus, we sear-
ched for mitochondrial processing peptidase (MPP) and
mitochondrial intermediate peptidase (MIP) consensus
motifs and found partially overlapping R-2, R-3, and R-10
motifs22 in sequence ARVLAPGGQD of FoxO3A region
98–108 (Supplementary Figure S2a). Thus, we generated a
FLAG-tagged vector encoding for FoxO3A-Δ80-108 and
found that it was able to localize at -but impaired in
Fig. 3 (See legend on next page.)
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translocating into- the mitochondria, as shown by the
absence of the 70 kDa band (Fig. 2e).
We then purified mitochondria from metabolically
stressed HCT116 and HEK293 cells and performed an
immunoblot analysis of endogenous FoxO3A with two
antibodies, one directed against the N-terminus, which
only detected a single band of around 90 kDa in the whole
mitochondria fraction, and the other targeting the C-
terminal domain, which recognized both the 90 kDa and
the 70 kDa bands in whole mitochondria and only the 70
kDa band inside the organelles (Fig. 2f). Moreover, genetic
silencing using two FoxO3A-specific siRNAs confirmed
that the 70 kDa band detected inside the mitochondria is a
shorter form of endogenous FoxO3A (Fig. 2g). Further PK
protection assays confirmed that endogenous FoxO3A is
translocated into the mitochondria and reaches the matrix
in its cleaved 70 kDa form (FoxO3A-cl.) (Supplementary
Figure S2b, S2c). These results were corroborated by
immunoblot analysis of mitoplasts from swollen mito-
chondria treated with PK (Supplementary Figure S2b,
S2d).
These data indicate that FoxO3A N-terminus (aa
1–148) is required for proper recruitment to the mito-
chondria, with residues 98–108 being necessary for
FoxO3A cleavage and import into the mitochondrial
matrix. Interestingly, this region is specific to FoxO3A (it
is not conserved in other human FoxO members) (Sup-
plementary Figure S3), and is evolutionarily conserved
across species (Supplementary Figure S4b).
Phosphorylation at S12 and S30 of FoxO3A N-terminus is
required for mitochondrial accumulation in metabolically
stressed cancer cells
FoxO3A N-terminus (aa 1–148) has been poorly char-
acterized, except for threonine 32, which represents a
well-known target of AKT13. Thus, we searched for novel
residues that could be targeted by signaling pathways
transducing extracellular stimuli. Based on our in silico
analysis with NETPHOS 2.0 and DISPHOS 1.3 servers,
only six serines (12, 26, 30, 43, 48 and 55) reached a
significant threshold score (>0.6) with both tools (Sup-
plementary Table S1). Furthermore, all these residues
have been described as being phosphorylated in vivo in
different types of human cancers23–29.
To test whether these serines were involved in FoxO3A
accumulation into the mitochondria, we mutagenized
them to non-phosphorylatable alanine residues (Fig. 3a
and Supplementary Figure S5a) and expressed the indi-
cated FoxO3A FLAG-tagged proteins in glucose-
restricted cancer cells. Our data show that alanine sub-
stitution at position 12 or 30 impaired the ability of full-
length FoxO3A (FoxO3A-fl.) to be recruited at the outer
membrane and to localize inside the mitochondria in its
cleaved form (FoxO3A-cl.) (Fig. 3b). Furthermore, con-
comitant substitution of both serines (S12A/S30A) com-
pletely abrogated FoxO3A mitochondrial localization
(Fig. 3c, d), suggesting that S12 and S30 are both required
for FoxO3A translocation into the mitochondria in
metabolically stressed cancer cells. These data were con-
firmed with a vector encoding for a FoxO3A mutant
lacking the initial 30 residues of the N-terminal domain
[FoxO3A-Δ1-30-FLAG], which was found to be severely
impaired in mitochondrial localization (Fig. 3e).
Since AMPK is involved in FoxO3A mitochondrial
accumulation in normal cells under glucose deprivation20,
we performed a comparative analysis between well-known
AMPK consensus phosphorylation motifs and the amino
acid sequence surrounding FoxO3A serines located at the
N-terminal domain. Our findings suggest that S30 could
represent a novel AMPK phosphorylation site in FoxO3A
(Supplementary Table S2). Likewise, Kinasephos 2.0
analysis predicted that S12 could be part of an ERK
consensus phosphorylation motif (Ser-Pro). Thus, we
characterized glucose-restricted HCT116 cells and
(see figure on previous page)
Fig. 3 Phosphorylation at S12 and S30 of FoxO3A N-terminus is required for mitochondrial accumulation in metabolically stressed cancer
cells. a Scheme of FoxO3A-WT-FLAG and mutated FoxO3A-FLAG plasmids obtained by site-directed mutagenesis. b, c HCT116 cells were transfected
with the indicated FoxO3A-WT-FLAG and mutant plasmids for 48 h. Upon LG (0.75 mM glucose, 24 h), total and mitochondrial proteins were analyzed
by immunoblot. d HCT116 cells were transfected with the indicated FoxO3A-WT-FLAG and mutant plasmids for 48 h. Upon LG (24 h), purified
mitochondrial fractions were treated with PK and analyzed by immunoblot. BCL2 outer membrane control, TFAM mitochondrial matrix control. e
HCT116 cells were transfected with FoxO3A-WT-FLAG or FoxO3A-Δ1-30-FLAG for 48 h, cultured in LG (24 h). f Total proteins were isolated from
HCT116 cells grown in standard and LG (24 h) conditions and analyzed by immunoblot. g Pharmacological inhibition of MEK using PD98059 in
HCT116 cells cultured in LG (24 h). Total and mitochondrial proteins were analyzed by immunoblot. h Pharmacological inhibition or activation of
AMPK using compound C (CC, 5 μM) or AICAR (5 mM), respectively, in HCT116 cells cultured in LG (24 h). Total and mitochondrial proteins were
analyzed by immunoblot. b, c, e–h β-actin and TFAM were used as total lysate and mitochondrial fraction controls, respectively. i Scheme of GST-
FoxO3A recombinant proteins. l, m In vitro kinase assays performed with the indicated GST-FoxO3A(1–148) and mutant recombinant proteins as
substrates, in the presence of recombinant ERK (l) or recombinant AMPK (m). In both assays, GST-FoxO3A(386–525) was used as a positive control.
GST-empty protein was used as a negative control. Coomassie gel staining (lower panels) was used as a loading control. fl. full-length FoxO3A, cl.
cleaved FoxO3A, N-term. N-terminal domain, FKH-DBD forkhead DNA-binding domain, NLS nuclear localization signal, TAD transactivation domain,
C-term. C-terminal domain. The presented results are representative of at least three independent experiments
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observed that both AMPK and ERK kinases were
phospho-activated in these culture conditions (Fig. 3f) and
could be localized at the mitochondria together with
FoxO3A (Supplementary Figure S5b). Of note, pharma-
cological inhibition of the MEK/ERK or the AMPK
pathway by PD98059 or compound C (CC), respectively,
significantly prevented FoxO3A localization at (FoxO3A-
fl.) and accumulation into (FoxO3A-cl.) the mitochondria
(Fig. 3g, h). Furthermore, activation of AMPK by AICAR
significantly induced FoxO3A mitochondrial processing
and import, as shown by its cleaved form levels, even in
HG culture conditions (Fig. 3h).
To confirm the hypothesis that S12 and S30 were tar-
geted by ERK and AMPK, respectively, we generated two
GST-FoxO3A constructs, one encoding for the N-
terminal domain [GST-FoxO3A(1–148)], and the other
for a region encompassing residues 386–525 [GST-
FoxO3A(386–525)] and containing serines previously
shown to be targeted by both AMPK (S399 and S413)12
and ERK (S425)30 (Fig. 3i). Moreover, the GST-FoxO3A
(1–148) vector was mutagenized by serine/alanine sub-
stitution at positions 12 and/or 30 to obtain the con-
structs GST-FoxO3A(1–148)S12A, GST-FoxO3A(1–148)
S30A and GST-FoxO3A(1–148)S12A/S30A (Fig. 3i). The
indicated purified proteins were subjected to a kinase
assay to test the ability of AMPK and ERK to directly
phosphorylate their candidate residues in vitro. Data
presented in Fig. 3l show that ERK could efficiently
phosphorylate GST-FoxO3A(1–148) as well as the posi-
tive control [GST-FoxO3A(386–525)], and that the S12A
substitution was sufficient to significantly abrogate 32P.
incorporation in GST-FoxO3A(1–148). Similar results
were obtained with the S12A/S30A double-mutant, indi-
cating that ERK directly phosphorylated FoxO3A at serine
12. To ascertain whether S30 could be phosphorylated by
AMPK, we assayed GST-FoxO3A(1–148) and GST-
FoxO3A(385–525) with AMPK and found that AMPK
efficiently phosphorylated FoxO3A N-terminus in vitro
(Fig. 3m). Serine-to-alanine substitution at position 30
abolished the radioactive labeling and similar results were
obtained with the S12A/S30A double-mutant, thus indi-
cating that AMPK phosphorylates FoxO3A at S30
(Fig. 3l).
Of note, S30 is more conserved across species than S12
(Supplementary Figure S4a) and is part of a highly con-
served subdomain, which is shared by other human
FoxOs, while S12 is not (Supplementary Figure S3).
mtFoxO3A regulates the expression of the mitochondrial
genome in metabolically stressed cancer cells
To functionally characterize the newly identified
FoxO3A cleaved form, we expressed the HA-FoxO3A-
FLAG vector (Fig. 4a) in HCT116 cancer cells. Chromatin
immunoprecipitation (ChIP) analysis performed using an
anti-FLAG or an anti-HA antibody showed that the
cleaved form, recognized only by the anti-FLAG antibody,
could efficiently bind the D-loop of mtDNA at FHRE
consensus sites under metabolic stress conditions
(Fig. 4b). Further, ChIP analyses performed on endogen-
ous proteins from mitochondria purified from different
human cancer cell lines and HEK293 cells confirmed that
FoxO3A-cl. is recruited at FHRE sites together with
SIRT3, TFAM and mtRNAPOL in glucose-restricted cells
(Fig. 4c, f and Supplementary Figure S6a, S6b), and that
these proteins form a complex into the matrix (Fig. 4e).
Specificity was ensured by a parallel analysis carried out in
mitochondria purified from mtDNA-depleted (Rho0)
HT29 cells31, which served as a negative control (Fig. 4f).
Importantly, the presence of the FoxO3A-cl./SIRT3/
TFAM/mtRNAPOL complex on mtDNA correlated well
with increased expression of all mitochondrial transcripts
in LG conditions, as shown by quantitative RT-PCR
(see figure on previous page)
Fig. 4 Mitochondrial FoxO3A regulates mitochondrial gene expression in metabolically stressed cancer cells. a Scheme of plasmids used. b
ChIP analysis of exogenous FoxO3A recruitment at FHRE #1–2 sites on mtDNA (FHRE #1: bp 14,963–15,110; FHRE #2: bp 15,400–15,469) upon LG (0.75
mM glucose, 24 h) in HCT116 cells transfected with HA-FoxO3A-WT-FLAG. c, f ChIP analysis of endogenous FoxO3A recruitment at FHRE #1–2 sites on
mtDNA in HCT116 (c), and HT29 and Rho0 HT29 (negative control) (f) cells upon LG (24 h). d, g Mitochondrial gene regulation in HCT116 (d) and
HT29 (g) cells upon LG (24 h) assessed by RT-PCR. Black bars: ATPase 6 and 8 genes; white bars: COX1, COX2, and COX3 genes; gray bars: ND1, ND2,
ND3, ND4, ND4L, ND5, and ND6 genes; light gray bar: CYTOCHROME B gene. The dotted line corresponds to the expression levels detected in cells
cultured in HG. e Co-immunoprecipitation analysis with the indicated antibodies of PK-treated HCT116 mitochondrial fractions upon LG (24 h). h
Upper panel: scheme of gRNA location in human FoxO3A locus. Targeting sites and proto-spacer adjacent motifs (PAMs) and the deleted region are
indicated. Lower panel: immunoblot analysis of HCT116-FoxO3A+/+ and HCT116-FoxO3A−/− cells with different anti-FoxO3A antibodies upon 2-DG (1
mM, 6 h) treatment. i–p HCT116-FoxO3A−/− cells were transfected with the indicated FoxO3A plasmids for 48 h and treated with 2-DG (1 mM, 6 h). i
Immunoblot analysis of total and mitochondrial proteins. l, m, o, p ChIP analysis of exogenous FoxO3A recruitment at FHRE p21–p27 sites on nuclear
DNA (l, o) and FHRE #1–2 sites on mtDNA (m, p). n Immunoblot analysis of nuclear and mitochondrial proteins. b, c, f, l, m, o, p Anti-IgGs were used
as controls. e, h, i, n β-actin, TFAM, and LAMIN B were used as total, mitochondrial and nuclear lysate controls, respectively, as appropriate. fl. full-
length FoxO3A, cl. cleaved FoxO3A, N-term. N-terminal domain, FKH-DBD forkhead DNA-binding domain, NLS nuclear localization signal, TAD
transactivation domain, C-term. C-terminal domain. The presented results are representative of at least three independent experiments. Where
applicable, data are presented as mean ± SEM and significance was calculated with Student’s t test; *p < 0.05, **p < 0.01, and ***p < 0.001
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analysis of mtRNA (Fig. 4d, g and Supplementary Figure
S6a, S6b).
To dissect FoxO3A nuclear vs. mitochondrial activity in
cancer cells under metabolic stress, we first generated a
FoxO3A knockout HCT116 cell line (HCT116-FoxO3A−/−)
with the CRISPR/Cas9 system for genome editing
(Fig. 4h). Then, we reconstituted FoxO3A expression by
transfecting these cells with wild-type FoxO3A or the
unphosphorylatable mutant FoxO3A–S12A/S30A or a
newly generated mutant, FoxO3A-S12D/S30D, where
serines were replaced with aspartic acid residues to mimic
phosphoserines (Fig. 4a). As shown in Fig. 4i, the phos-
homimetic mutant (FoxO3A-S12D/S30D) strongly accu-
mulated into the mitochondria, also in the absence of
stress (HG), where it bound mtDNA and induced the
expression of mitochondrial-encoded proteins, while
FoxO3A-S12A/S30A failed to do so (Fig. 4m and Sup-
plementary Figure S6c, S6d). Importantly, both FoxO3A
mutants were still able to enter the nucleus and bind
FHRE sites at the promoters of p21 and p27 target genes
under metabolic stress (Fig. 4l). In the same cellular sys-
tem, another FoxO3A mutant, FoxO3A-Δ242-271, in
which we deleted the nuclear localization signal (NLS)32,
was unable to enter the nucleus (Fig. 4n) and bind p21/
p27 FHRE sites (Fig. 4o), but was still capable of entering
the mitochondria and bind FHRE sites at the D-Loop of
mtDNA in metabolically stressed cancer cells (Fig. 4p).
FoxO3A accumulation into the mitochondria only requires
the AMPK signal in normal cells and tissues under nutrient
shortage
To explore FoxO3A “mitochondrial code” in normal
cells, we transfected NIH3T3 fibroblasts with FoxO3A-wt,
FoxO3A-S12A or FoxO3A-S30A. Of note, normal fibro-
blasts only required AMPK activation to induce
mtFoxO3A accumulation, as replacement of serine 30
with a non-phosphorylatable alanine was sufficient to
prevent FoxO3A mitochondrial localization under glu-
cose restriction (Fig. 5a, b).
Then, to corroborate our data in vivo, we subjected mice
to overnight fasting (18 h), a procedure known to sig-
nificantly lower plasma glucose levels33, and purified
mitochondria from kidney and liver. Immunoblot analysis
revealed the accumulation of both FoxO3A forms in
fasted mice, suggesting that nutrient shortage caused
localization of the transcription factor at the outer mito-
chondrial membrane (FoxO3A-fl.) and its subsequent
import, cleavage, and translocation into the mitochondrial
matrix (FoxO3A-cl.) (Fig. 5d, e). PK treatment of mouse
mitochondria confirmed that the cleaved form is detect-
able also in vivo into the mitochondrial matrix (Fig. 5e).
To get the full picture, we characterized the status of
AMPK and ERK in kidney and liver of fasted mice
(Fig. 5c). Only AMPK was found to be significantly
activated in these animals upon nutrient shortage, which
supports its role in the signal transduction pathways
leading to FoxO3A mitochondrial translocation.
These results suggest that normal cells and tissues
under metabolic stress only require the AMPK signal on
S30 to direct FoxO3A into the mitochondria, whereas
ERK involvement in FoxO3A mitochondrial localization is
unique to tumor cells.
Role of mtFoxO3A in cancer cell response to metabolic
stress
To evaluate the role of FoxO3A in tumor cells subjected
to metabolic stress or treated with cancer therapeutics,
HCT116-FoxO3A+/+ and HCT116-FoxO3A−/− cells
were cultured in LG conditions or in the presence of
drugs currently administered to colorectal cancer patients
and whose activity has been shown to involve FoxO3A in
cellular models (metformin, cisplatin, irinotecan, 5-
fluorouracil and etoposide)8,34–37. Surprisingly, HCT116-
FoxO3A−/− cells were more sensitive to metabolic stress
and chemotherapeutics than their wild-type isogenic
counterparts, suggesting that the presence of FoxO3A
results in resistance and survival (Fig. 6a). Conversely,
HCT116-FoxO3A+/+ cells were more sensitive to met-
formin treatment than HCT116-FoxO3A−/− cells
(Fig. 6a). Then, we cultured several human cancer cell
lines and HEK293 cells in LG conditions to assay their
resistance under metabolic stress. Our results showed that
the higher the amount of mtFoxO3A they accumulated,
the more they survived in LG cultures (Fig. 6b), suggesting
that mtFoxO3A could represent a survival factor in these
conditions. To test this hypothesis, we reconstituted
FoxO3A expression in HCT116-FoxO3A−/− cells by
transfection with FLAG-tagged vectors encoding for
FoxO3A-wt, the unphosphorylatable double-mutant
FoxO3A-S12A/S30A (impaired in its mitochondrial
localization, but still able to localize into the nucleus and
bind target genes, see Fig. 4i–m) or FoxO3A-Δ242-271
(which lacks the NLS, but is able to enter the mitochon-
dria and bind FHRE sites at mtDNA, see Fig. 4n–p) and
cultured them in LG conditions. Our results showed that
reconstitution of FoxO3A-wt expression results in
increased survival; of note, FoxO3A-Δ242-271 was still
able to rescue metabolic stress-dependent cell death,
while the mutant impaired in mitochondrial localization
failed to do so (Fig. 6c). Furthermore, analysis of FoxO3A
target gene expression revealed that both the wild-type
form and the Δ242-271 mutant were able to activate
mitochondrial transcription in surviving cells, while the
FoxO3A-S12A/S30A mutant contributed to apoptosis
induction in metabolically stressed cancer cells by pro-
moting BIM transcription (Fig. 6d). Subsequently, we
transfected FoxO3A knockout cells with GFP-tagged
vectors encoding for FoxO3A-wt, FoxO3A-S12A/S30A,
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or FoxO3A-Δ242-271, then we induced metabolic stress
by adding 2-DG and performed TMRE staining to
visualize the polarization status of mitochondrial mem-
branes in GFP-positive cells. Our data indicate that
mtFoxO3A is required to maintain the membrane
potential of functionally active and healthy mitochondria
in cancer cells subjected to metabolic stress (Fig. 6e).
Indeed, TMRE failed to stain mitochondria of HCT116-
FoxO3A−/− cells transfected with the FoxO3A-S12A/
S30A mutant (Fig. 6e), as they were undergoing apoptosis
(Fig. 6c). These results highlighted the functional impor-
tance of FoxO3A S12 and S30 residues, together with the
activation of pathways dictating their phosphorylation
(Fig. 6c), in cancer cell resistance to metabolic stress, and
prompted us to evaluate the inhibition of the MEK/ERK
and/or the AMPK pathway in HCT116-FoxO3A+/+ cells
cultured in LG conditions. Of note, trametinib (a MEK
inhibitor approved by the FDA for clinical use) and CC
(an AMPK inhibitor) showed a synergistic cytotoxic effect
in metabolically stressed cancer cells (Fig. 6f). In order to
confirm these results in vivo, we injected HCT116-
FoxO3A+/+ cells in nude mice and treated growing
tumors with 2-DG to induce metabolic stress. Our results
reveal that activation of both the MEK/ERK and the
Fig. 5 FoxO3A accumulation into the mitochondria only requires the AMPK signal in normal cells and tissues under nutrient shortage. a
Immunoblot analysis of total proteins isolated from NIH3T3 cells upon LG (0.75 mM glucose, 24 h). β-actin: loading control. b Immunoblot analysis of
total and mitochondrial proteins isolated from NIH3T3 cells transfected with the indicated plasmids for 48 h and subjected to LG (24 h). β-actin and
HSP60 were used as total lysate and mitochondria controls, respectively. c Left panel: immunoblot analysis of total proteins isolated from kidney and
liver of fed or fasted (18 h) mice. β-actin: loading control. Right panel: densitometric analysis of the phosphorylated forms of AMPK and ERK
normalized against total AMPK and ERK, respectively, and the loading control. d Left panel: immunoblot analysis of mitochondrial proteins isolated
from kidney and liver of fed or fasted (18 h) mice. HSP60: loading control. Right panel: densitometric analysis of full-length and cleaved FoxO3A
normalized against the mitochondrial fractionation loading control. e Immunoblot analysis of mitochondrial proteins isolated from the liver of fed or
fasted (18 h) mice in the presence or absence of PK. BCL2: outer membrane control, HSP60: mitochondrial matrix control. fl. full-length FoxO3A, cl.
cleaved FoxO3A. The presented results are representative of at least three independent experiments. Where applicable, data are presented as mean
± SEM and significance was calculated with Student’s t test; *p < 0.05, **p < 0.01, and ***p < 0.001
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AMPK pathways is induced in tumor tissues upon
metabolic stress, together with FoxO3A mitochondrial
localization, similar to what happens in culture (Fig. 6g).
Role of mtFoxO3A in cancer cell response to
chemotherapeutic agents
To investigate the role of mitochondrial vs. nuclear
FoxO3A in cancer cell response to chemotherapeutic
agents, HCT116-FoxO3A−/− cells were transfected with
FLAG-tagged vectors encoding for FoxO3A-wt, FoxO3A-
S12A/S30A or FoxO3A-Δ242-271 and then cultured in
the absence or presence of irinotecan (CPT-11), cisplatin
(CDDP), 5-fluorouracil (5-FU) or etoposide (VP-13).
Consistent with the data obtained in HCT116-FoxO3A−/−
vs. HCT116-FoxO3A+/+ cells (Fig. 6a), reconstitution of
wild-type FoxO3A expression resulted in increased
survival (Fig. 7a and Supplementary Figure S7a–c).
Moreover, the mitochondrial localization-impaired
unphosphorylatable mutant was unable to rescue
chemotherapy-induced apoptosis (Fig. 7a and Supple-
mentary Figure S7a–c), while it could activate BIM tran-
scription to contribute to the apoptotic response (Fig. 7a,
b), in line with our results in metabolically stressed cells.
The FoxO3A-Δ242-271 mutant behaved similar to
FoxO3A-wt and both were able to activate mitochondrial
gene expression in chemotherapy-induced cellular stress
conditions (Fig. 7a, b and Supplementary Figure S7a–c).
Molecular analysis of transfected HCT116-FoxO3A−/−
cells showed activation of the MEK/ERK, but not the
AMPK pathway, in response to chemotherapy (Fig. 7a,
lower panel). Indeed, only serine 12 of FoxO3A was
required to elicit chemoresistance in these conditions
(Fig. 7c). Consistently, in HCT116-FoxO3A+/+ xeno-
grafted tumors treated with CDDP, we detected activation
of the MEK/ERK, but not the AMPK pathway, and
accumulation of FoxO3A into the mitochondria (Fig. 7d).
Of note, the MEK inhibitor trametinib and CPT-11
showed a synergistic cytotoxic effect in HCT116-
FoxO3A+/+ cells (Fig. 7e).
An opposite behavior was observed when HCT116-
FoxO3A+/+ and HCT116-FoxO3A−/− cells were treated
with metformin. Indeed, molecular analysis of HCT116-
FoxO3A+/+ cells indicated that metformin only activates
AMPK and induces cells to undergo apoptosis (Fig. 7f).
Reconstitution of FoxO3A expression with the wild-type
form or the FoxO3A-Δ242-271 mutant significantly
increased cell death (Fig. 7g), suggesting that mtFoxO3A
is required for apoptosis induction by metformin. Indeed,
reconstitution with a vector encoding for the FoxO3A-
S30A mutant was sufficient to reduce cell death to mock-
transfected cell levels. These results indicate that met-
formin can induce apoptosis via the AMPK-mtFoxO3A
axis. Consistently, metformin showed a synergistic cyto-
toxic effect with irinotecan in HCT116-FoxO3A+/+ cells
(Fig. 7h).
Discussion
Recent advances in cancer understanding suggest that
the “Warburg effect” should be reconsidered in its inter-
pretation of the role of mitochondria in tumorigenesis.
Indeed, although aberrant tumor cell growth is frequently
associated with alterations of biochemical metabolism,
mitochondrial function is not usually impaired2–4. In fact,
large studies conducted to examine the mutational status
of the mitochondrial genome in tumors revealed that
detrimental and pathogenic mtDNA mutations are
negatively selected7,38,39, implying that selective pressure
for mitochondrial genome function preservation is a
common feature in human tumors5–7,40. In addition to
respiration, mitochondria are the powerhouse for
(see figure on previous page)
Fig. 6 mtFoxO3A is involved in cancer cell response to metabolic stress. a HCT116-FoxO3A+/+ and HCT116-FoxO3A−/− cells were subjected to
different treatments: glucose restriction (LG, 0.75 mM glucose, 24 h), metformin (MET, 10 μM, 72 h), cisplatin (CDDP, 30 μM, 48 h), irinotecan (CPT-11,
30 μM, 24 h), 5-fluorouracil (5-FU, 2 μM, 24 h) and etoposide (VP-13, 40 μM, 24 h). Relative cell viability and relative cell death were calculated. b
Correlation between LG-resistance (days) and mitochondrial FoxO3A (mtFoxO3A) protein levels in different human cell lines (HCT116 and HT29
colorectal cancer cells, HEK293 embryonic kidney cell, DU145 prostate cancer cells, A549 lung cancer cells, MDA-MB-468 breast cancer cells and
OVCAR3 ovarian cancer cells). a.u. arbitrary units. c HCT116-FoxO3A−/− cells were transfected with the indicated plasmids (48 h) and subjected to LG
(24 h). Upper panel: relative cell viability and relative cell death. Lower panel: immunoblot analysis of total proteins. β-actin: loading control. d
Transcription analysis of selected mitochondrial (ND6 and COX1) and nuclear (BIM) genes by RT-PCR in HCT116-FoxO3A−/− cells transfected with the
indicated plasmids (48 h) and subjected to LG (24 h). e HCT116-FoxO3A−/− cells, transfected with the indicated plasmids (48 h), were subjected to
metabolic stress with 2-DG (1 mM, 6 h). The graph reflects the quantification of tetramethylrhodamine ethyl ester (TMRE) fluorescence of active
mitochondria in transfected cells. f Clonogenic assay on HCT116-FoxO3A+/+ cells cultured in LG (24 h) and treated with increasing concentrations of
trametinib and/or compound C, as indicated, for 24 h. Cell growth percent inhibition at each drug concentration is presented. g Left panel:
immunoblot analysis of total and mitochondrial proteins isolated from tumors (n≥ 7 for each group) derived from HCT116-xenografted nude mice
subjected to 2-DG treatment (100mg/kg, 6 days). β-actin and HSP60 were used as total and mitochondrial loading control, respectively. Right panel:
densitometric analysis of full-length and cleaved FoxO3A normalized against the mitochondrial loading control and the results of the densitometric
analysis of the phosphorylated-AMPK and ERK normalized against total AMPK and ERK, respectively, and the loading control. Data are presented as
mean ± SEM and significance was calculated with Student’s t test; *p < 0.05, **p < 0.01, and ***p < 0.001
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bioenergetics and biosynthetic pathways that are required
for tumorigenesis7. Thus, understanding the role of
mitochondrial function in cancer might reveal novel
approaches to targeted cancer therapy. Indeed, recent
reports suggested that cancer cells are highly susceptible
to the inhibition of oxidative phosphorylation, and that
mitochondrial translation inhibitors can act as sensitizers
to cancer therapeutics and chemotherapy41,42. Con-
sistently, our results indicated that MEK inhibition by
trametinib synergized with AMPK inhibitors in reducing
survival under metabolic stress, and with irinotecan in
inducing cytotoxicity in colorectal cancer cells (Fig. 8).
Importantly, combination therapy with MEK inhibitors
and chemotherapeutic agents is predicted to overcome
resistance mechanisms and potentiate the antitumor
activity of each single agent, and various phase II/III trials
based on such approaches are currently ongoing43.
Metformin is a biguanide drug commonly used in dia-
betes treatment that has shown anticancer activity in
diabetic patients44,45. It has been recently proposed that
metformin inhibits the activity of complex I of the mito-
chondrial machinery responsible for oxidative phosphor-
ylation, the same mechanism inducing AMPK activation
in cultured cells46,47. In our cellular model, metformin
activity was mediated by AMPK and required mtFoxO3A
to elicit its pro-apoptotic effect in cancer cells and che-
mosensitization to irinotecan (Fig. 8). Importantly, several
phase II/III clinical trials are currently evaluating the
efficacy of metformin in association with chemother-
apeutic agents as well as its chemoprevention activity as a
single agent44,45.
The interplay between the MEK/ERK and the AMPK
cascades, which converge on the N-terminal domain of
FoxO3A, represents the first chapter of the mitochondrial
tale of the FoxO3A code. Further studies are needed to
establish whether other signaling pathways actually target
(see figure on previous page)
Fig. 7 mtFoxO3A is involved in cancer cell response to chemotherapeutic agents. a–c HCT116-FoxO3A−/− cells were transfected with the
indicated plasmids for 48 h and then treated with irinotecan (CPT-11, 30 μM, 24 h). a Upper panel: relative cell viability and relative cell death. Lower
panel: immunoblot analysis of total proteins. β-actin: loading control. b Transcription analysis of selected mitochondrial (ND6 and COX1) and nuclear
(BIM) genes by RT-PCR. c HCT116-FoxO3A−/− cells were transfected with the indicated plasmids for 48 h and then treated with irinotecan (CPT-11, 30
μM, 24 h). Relative cell viability and relative cell death were calculated. d Left panel: immunoblot analysis of total and mitochondrial proteins isolated
from tumors (n≥ 7 for each group) derived from HCT116-xenografted nude mice subjected to cisplatin treatment (CDDP, 2 mg/kg, 6 days). β-actin
and HSP60 were used as total lysate and mitochondrial fraction controls, respectively. Right panel: densitometric analysis of full-length and cleaved
FoxO3A normalized against the mitochondrial fractionation loading control and the results of the densitometric analysis of the phosphorylated forms
of AMPK and ERK normalized against total AMPK and ERK, respectively, and the loading control. e Clonogenic assay on HCT116-FoxO3A+/+ cells
treated with increasing concentrations of trametinib (24 h) and/or irinotecan (24 h), as indicated. f Immunoblot analysis of total proteins isolated from
HCT116-FoxO3A+/+ cells upon metformin treatment (MET, 10 μM, 72 h). β-actin: loading control. g HCT116-FoxO3A−/− cells were transfected with the
indicated plasmids for 48 h and then treated with metformin (MET, 10 μM, 72 h). Relative cell viability and relative cell death were calculated. h
Clonogenic assay on HCT116-FoxO3A+/+ cells treated with increasing concentrations of metformin (24 h) and/or irinotecan (24 h), as indicated. e, h
Cell growth percent inhibition at each drug concentration is presented. The data presented are the mean of at least three independent experiments.
Where applicable, data are presented as mean ± SEM and significance was calculated with Student’s t test; *p < 0.05, **p < 0.01, and ***p < 0.001
Fig. 8 FoxO3A represents a survival factor in metabolically
stressed cancer cells. Normal cells and tissues under metabolic stress
require only the AMPK signal on S30 to direct FoxO3A into the
mitochondria. It seems that ERK involvement in FoxO3A mitochondrial
localization is exclusive to tumor cells, which reveals a critical
difference between normal and cancer cells that could be exploited
for cancer therapeutics. In metabolically stressed cancer cells, FoxO3A
is recruited to the mitochondria through activation of MEK/ERK and
AMPK, which phosphorylate serine 12 and 30, respectively, on FoxO3A
N-terminal domain. Subsequently, FoxO3A is imported and cleaved to
reach mitochondrial DNA, where it activates expression of the
mitochondrial genome to support mitochondrial metabolism. In
cancer cells treated with chemotherapeutic agents, accumulation of
FoxO3A into the mitochondria promoted survival in a MEK/ERK-
dependent manner, while mitochondrial FoxO3A was required for
apoptosis induction by metformin
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FoxO3A N-terminus to modulate its mitochondrial
localization and function and which stimuli do they
respond to. This will be instrumental to devise persona-
lized therapeutic strategies -employing molecularly tar-
geted drugs- aimed at manipulating cellular metabolism
to counteract cancer initiation and progression.
Material and methods
Cells culture and reagents
NIH3T3, MEFs, HT29, HT29 Rho0, HCT116,
HCT116-FoxO3A−/−, HeLa, LS174T, MDA-MB-468,
OVCAR3, A549, and SW-480 cells were cultured in
DMEM high glucose (HG), without pyruvate (#11360-
070, Gibco, Carlsbad, California) with 10% FBS (#0270-
106, Gibco) and 100 IU/ml penicillin–streptomycin
(#15140-122, Gibco). BT474, EFM19 and Caco2 cells
were maintained in the same conditions with 5% and
20% FBS, respectively. HEK293 cells were supple-
mented with 1% pyruvate and NEAA (#11140, Sigma
Aldrich, ST. Louis, Missouri). DU145 cells were cul-
tured in RPMI high glucose (HG), without pyruvate
(#21875-034, Gibco) with 10% FBS (Gibco) and 100 IU/
ml penicillin–streptomycin (Gibco). All cell lines were
glucose-restricted by using DMEM 0.75 mM (LG) as
previously described20. Compound C (5 μM, #171260),
AICAR (5 mM, #A9978), PD98059 (0,02 mM, #P215),
2-deoxy-glucose (1 mM, #D8375), iodoacetic acid (0,5
μM, #I4386), metformin (10 μM, #D150959), 5-
fluorouracil (2 μM, #F6627), cisplatin (30 μM, #P4394),
etoposide (40 μM, #E1383) and irinotecan (30 μM,
#347609) were all from Sigma; trametinib (#S2673) was
from Selleckchem (Munich, German).
Animal care and use
C57/Bl6J male pure strain mice were bred on a 12 h
light/dark cycle and fed with standard diet. Eight- to ten-
week-old mice were divided in two experimental groups:
free food access group (fed) and 18-h fasted group. Mice
were killed at the beginning of the light cycle in order to
avoid circadian variation of the gene expression profile.
Brain, kidney, lung, pancreas, colon, and liver were
chopped into small pieces with a razor blade and then
disaggregated using a Medimachine (Becton Dickinson,
NJ, USA). Cells were collected and processed for total
protein analysis and/or mitochondria isolation as pre-
viously described48.
Female CD-1 athymic nude mice (6–8-week-old) were
obtained from Charles River Laboratories (Wilmington,
MA). To develop xenograft tumors, 10× 106 HCT116
cells were injected subcutaneously into the flanks (0.2 ml
per flank) of CD-1 mice. The volume of the tumors was
measured every 2–3 days and calculated using the fol-
lowing formula: volume (mm3)= (width)2× length× 0.5.
When the tumor volume reached 60mm3, mice were
randomized into different treatment groups. Cisplatin (2
mg/kg) or 2-deoxygluocose (100 mg/kg) were given
intraperitoneally once every 3 days. Control groups
received the vehicle only (normal saline). Mice were
treated for 6 days and tumor volume and body weight
were recorded every 2–3 days. At the end of the treat-
ment, mice were killed and tumors explanted for immu-
noblot analysis. Animals were cared for following the
institutional guidelines, in compliance with national and
international laws and policies.
Cloning
The plasmids described in the manuscript were obtained,
with specific primers, as previously described49. Site-directed
mutagenesis was performed using the Q5® Site-Directed
Mutagenesis Kit (#E05545, New England Biolabs, Ipswich,
MA) according to the manufacturer’s instructions. The
p3xFLAG-CMV14-FoxO3A construct was obtained starting
from the pECE-HA-FoxO3A plasmid (kindly provided by
Dr. M. Greenberg, Addgene, Cambridge, USA, plasmid
#1787); the p3xFLAG-CMV14-HA-FoxO3A construct was
obtained starting from the pECE-HA-FoxO3A plasmid,
followed by HA-FoxO3A fragment insertion into p3xFLAG-
CMV14-backbone. FoxO3A-Δ1–148-FLAG, FoxO3A-
S12A-FLAG, FoxO3A-S26A-FLAG, FoxO3A-S30A-FLAG,
FoxO3A-S43A-FLAG, FoxO3A-S48A-FLAG, FoxO3A-
S55A-FLAG, FoxO3A-S12A/S30A-FLAG, FoxO3A-S12D/
S30D-FLAG, FoxO3A-Δ1-30-FLAG, FoxO3A-Δ80-108-
FLAG and FoxO3A-Δ242-271-FLAG constructs were
obtained starting from the p3xFlag-FoxO3A plasmid.
FoxO3A(1–148)-GST and FoxO3A(386–525)-GST con-
structs were obtained starting from the p3xFLAG-FoxO3A
plasmid, followed by FoxO3A(1–148) and FoxO3A
(386–525)-GST insertion into a pGEX-4T-3 empty vector.
FoxO3A(1–148)S12A-GST, FoxO3A(1–148)S30A-GST,
FoxO3A(1–148)S12A/S30A-GST constructs were obtained
starting from the pGEX-4T-3-FoxO3A(1–148) plasmid. The
FoxO3A-WT-EGFP construct was obtained starting from
the p3xFlag-FoxO3A plasmid, followed by FoxO3A-WT
insertion into a pEGFP-N3 empty vector. FoxO3A–S12A/
S30A-EGFP and FoxO3A–Δ242-271-EGFP constructs were
obtained starting from the FoxO3A-WT-EGFP plasmid.
Site-directed mutagenesis primer sequences used in this
manuscript are available from the authors upon request.
Cell transfection and RNA interference
HCT116 and HEK293 cells were transiently transfected
with mammalian expression plasmids using TransIT-LT1
Transfection Reagent (#2300, Mirus, Madison, USA)
according to the manufacturer’s instruction.
For RNA interference, HCT116 cells were transfected
with 50 nM validated Silencer® Select Pre-Designed siRNA
(Thermo Fisher Scientific, Waltham, MA) directed against
FoxO3A by using the HiPerfect reagent (#301704,
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QIAGEN, Hilden, Germany) according to the manu-
facturer’s instructions. On-TARGET-plus control siRNAs
(Thermo Fisher Scientific) were used as a non-silencing
control. siRNA sequences used in this study:
siRNA1: 5′-CUCACUUCGGACUCACUUAtt-3′, 5′-
UAAGUGAGUCCGAAGUGAGca-3′
siRNA2: 5′-GCCUUGUCGAAUUCUGUCAtt-3′, 5′-
UGACAGAAUUCGACAAGGCac-3′
Protein expression and purification
NEB5-alpha bacterial strains (#C2987I, New England
Biolabs) transformed with different pGEX-4T3-GST-
FoxO3A constructs were grown in Luria Broth medium
with Ampicillin (#13399, Sigma) and induced with 0.5
mM IPTG when they reached the optical density of 0.6
(A600) at 37 °C, for 4 h. Cells were then collected by
centrifugation and pellets were lysed with B-PER lysis
buffer (#78248, Thermo Fisher Scientific). The lysate was
centrifuged at 15,000× g for 5 min at 4 °C. Recombinant
protein expression was confirmed by SDS-PAGE. Fusion
proteins were purified by affinity chromatography using
the GST Bulk Kit (#27-4570-01, GE Healthcare, Mil-
waukee, WI) according to the manufacturer’s instruc-
tions. GST-fused proteins were evaluated and quantified
by SDS-PAGE.
Mitochondria isolation and treatment
Mitochondria-enriched fractions were obtained as
described48. Briefly, cells were collected and centrifuged at
600× g at 4 °C for 10 min. Then, the pelleted cells were
resuspended in ice-cold IBc buffer (0.1 M Tris-MOPS, 0.1
M EGTA/Tris, 1M sucrose) and homogenized using a
Teflon-glass pestle. The homogenate was centrifuged at
600× g for 10 min at 4 °C and the supernatant was col-
lected and centrifuged at 7000× g for 10 min at 4 °C. The
pellet was resuspended in with ice-cold IBc and finally
centrifuged at 7000× g for 10 min at 4 °C. The obtained
mitochondria were treated with proteinase K 4 U/ml
(#17916, Ambion, Austin, TX) and/or Triton X-100
(0.25%) and analyzed by immunoblotting, as previously
described20.
Proteinase K protection assay
Mitochondrial fractions were resuspended in an iso-
tonic buffer50 and incubated with various concentrations
of proteinase K for 20min on ice. Digestion was stopped
with 2mM phenylmethylsulfonyl fluoride (PMSF). Mito-
chondrial proteins were isolated, separated by SDS/PAGE
and then detected by western blot analysis.
Mitochondrial swelling experiments
Mitochondrial fractions were resuspended in an hypo-
tonic buffer (10 mM MOPS-KOH) and incubated on ice
for 15min50. Half of the sample was then treated with
proteinase K (25 µg/ml) on ice for 20min. An aliquot of 2
mM PMSF was added to inactivate protease activity.
Mitochondria and mitoplasts were recentrifuged and
analyzed by SDS-PAGE.
Nuclear extraction
Nuclear extraction was performed using Nuclear
Extraction Kit according to the manufacturer’s instruc-
tions (#ab113474, Abcam, Cambridge, MA).
Chromatin immunoprecipitation (ChIP)
For mtDNA chromatin immunoprecipitaion to elim-
inate genomic DNA contamination, mitochondrial
fractions were treated with DNase I (4 U/100 mg wet
mitochondria) (#AM2224, Ambion) for 10 min on ice in
the presence of 2.5 mM MgCl2 in mitochondria isolation
buffer48. The reaction was stopped by adding EDTA
(final concentration 50 mM) into the mixture and crude
mitochondria were washed once. ChIP analysis was
performed as previously described20. Briefly, for-
maldehyde (#F8775, Sigma) was added directly to
mitochondrial fraction to a final concentration of 1%.
Cross-linking was allowed to proceed for 15 min at room
temperature and then stopped by the addition of glycine
(#G8898, Sigma) to a final concentration of 0.125M.
Cross-linked mitochondria were lysed in CLB (10 mM
Tris pH 8.0, 10 mM NaCl, 0.2% NP40) plus protease
inhibitors (#04693124001, Roche, Mannheim, Germany).
The mitochondrial fraction was enriched by differential
microcentrifugation. The chromatin solution was soni-
cated, cleared by centrifugation, and the supernatant was
divided into aliquots. One percent of the supernatant
was taken as input. Four micrograms of antibody per
point were used to immunoprecipitate chromatin-bound
complexes. Immunoprecipitation was performed on a
rotating platform overnight at 4 °C with the indicated
antibodies. IgG were used as unrelated antibodies.
Immunocomplexes were pulled down using protein G
(#10003D, GE Healthcare). Following extensive washing,
bound DNA was reverse cross-linked, purified using
phenol:chloroform (#AM9720, Sigma) and analyzed by
quantitative real-time PCR. ChIP assays on nuclear DNA
were performed using the MAGnify chromatin immu-
noprecipitation system (#A11250, Life Technologies,
Waltham, MA) according to the manufacturer’s
instructions. IgG antibodies were included in the kit and
1 μg of indicated antibodies were used for each assay.
Primer sequences used in this manuscript are available
from the authors upon request.
In vitro kinase assays
Purified AMPK (#171536, EMD Millipore, Billerica,
MA) and/or ERK (#31152, Active Motif, Carlsbad, CA)
were incubated with various recombinant substrates (0.5
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μg) in kinase reaction buffer [HEPES (32 mM) pH 7.4,
dithiothreitol (650 μM), Mg(CH3COO)2 (10 mM), BriJ-35
(0,012%), cold ATP (50 μM)] and 0.9–1.8 μCi of [γ-32P]
ATP (Perkin Elmer, Waltham, MA) at 30 °C for 30min.
For AMPK, AMP (100 μM) was added to the reaction.
Phosphorylation was detected by incorporation of radi-
olabeled [γ-32P]ATP.
Immunoblotting
Protein extracts were obtained by treating cells or
mitochondrial fractions with total lysis buffer (50 mM
Tris-HCl pH 7.4, 250mM NaCl, 5 mM EDTA, 0,1% Tri-
ton X-100, 1 mM DTT, 1 mM PMSF) supplemented with
protease and phosphatase inhibitors (Roche). Total of
15–20 mg of protein extracts from each sample were
denatured in 5× Laemmli sample buffer and loaded into
an SDS–poly-acrylamide gel for western blots analysis.
FoxO3A (CST #BK99199S), FoxO3A (CST #2497), COX4
3E11 (CST #4850), BCL2 50E3 (CST #2870), PDH C54G1
(CST #3205), FLAG M2 (Sigma #F1804), HA-Tag C29F4
(CST #3724), β-actin (CST #3700), AMPK-α Thr 172
(CST #2531), AMPK-α (CST #2532), p44/42 MAP2K1-
ERK1/2 Thr202/Tyr204 (CST #9106), p44/42 MA2PK1-
ERK1/2 (CST #9102), p-Acetyl-CoA Ser 79 (CST #3661),
TFAM D5C8 (CST #8076), HSP60 D307 (CST #4870),
IgG (CST #2729S), mtRNAPOL H300 (Santa Cruz #SC-
67350), SIRT3 D22A3 (CST #5490), LAMIN B1 (CST
#12586S) (Cell Signaling Technologies, Danvers, MA)
PARP1 (p85 fragment, G7341, Promega, Madison, WI),
ATPase 6 (#PA5-37129, Thermo Fisher Scientific), COXI
(#A6403, Molecular probes, Carlsbad, CA), ND6
(#A31857, Molecular probes) were used as primary anti-
bodies. HRPO-conjugated antibodies (#NA934V,
#NA931V, GE Healthcare) were used as secondary anti-
bodies and revealed using the ECL-plus chemilumines-
cence reagent (GE Healthcare). The densitometric
evaluation was performed by ImageJ software.
Microscopic quantification of viability and cell death
Cell viability and cell death of the reported cell lines
were scored by counting, as previously described34. The
supernatants (containing dead/floating cells) were col-
lected, and the remaining adherent cells were detached by
Trypsin/EDTA (#15400-054, Sigma). Cell pellets were
resuspended in 1× PBS and 10 μl were mixed with an
equal volume of 0.01% trypan blue solution. Viable cells
(unstained, trypan blue negative cells) and dead cells
(stained, trypan blue positive cells) were counted with a
phase contrast microscope. The percentages of viable and
dead cells were calculated.
Immunogold labeling
The immunogold labeling assay was performed as pre-
viously described20. Briefly, cells were fixed with 4%
formaldehyde and 0.005% glutaraldehyde, washed, incu-
bated with the primary antibody overnight, and then with
nanogold-conjugated Fab fragments of the secondary
antibodies (Nanoprobes, New York, USA) for 2 h. Nano-
gold particles were developed using the gold-enhance kit
(Nanoprobes). For each experimental condition, 20 cells
were analyzed. In each cell, 15 areas (mean 3× 106 nm2)
were randomly selected. Data presented in the “Results”
section were obtained by scoring the percentage of
FoxO3A-positive cells and counting the number of gold
particles per single mitochondria.
Real-time PCR
RNA extraction and real-time PCR were performed as
previously described51. Briefly, total RNA was extracted
with Trizol reagent (#15596-018, Invitrogen, Carlsbad,
CA) following the manufacturer’s instructions. Samples
were then treated with DNase-1 (#AM2224, Ambion) and
4 μg of total RNA was retrotranscribed using iScript™
cDNA Synthesis Kit (#1708891, BIORAD, Hercules, CA)
following the manufacturer’s instructions. PCRs were
carried out in triplicate using the SYBR Green PCR
Master Mix (#172-5275, BIORAD) on a QuantStudio3
Real-Time PCR System (Applied Biosystem, Carlsbad,
CA), according to the manufacturer’s instructions. Rela-
tive quantification was done using the ΔΔCt method.
Primer sequences used in this manuscript are available
from the authors upon request.
Co-immunoprecipitation (Co-IP)
For co-IP, cells (mitochondria) were lysed in IP lysis
buffer (50 mM Tris-HCl pH 7.4, 250mM NaCl, 5 mM
EDTA, 0,1% Triton X-100) supplemented with protease
inhibitors (Roche). Lysates were cleared by centrifugation
and incubated overnight at 4 °C with 1 μg of anti-FLAG,
anti-FoxO3A and/or IgG covalently bound to Protein G-
Sepharose (#10003D, GE Healtcare)/Protein A-Sepharose
(#17-0780-01, GE Healtcare). Immunocomplexes were
washed twice with lysis buffer, boiled in Laemmli sample
buffer and subjected to SDS-PAGE and western blot
analysis.
Prediction analysis
Analysis of the N-terminal region of FoxO3A (corre-
sponding to positions 1–148) was performed using the
NetPhos algorithm (http://www.cbs.dtu.dk/services/
NetPhos) and Disphos prediction (Disorder-Enhanced
Phosphorylation Sites Predictor, http://www.dAbi.temple.
edu/disphos/). The KinasePhos 2.0 (http://kinasephos2.
mbc.nctu.edu.tw/) prediction server was employed to
search for consensus phosphorylation motifs. A com-
parative analysis between AMPK consensus phosphor-
ylation motifs (UniProtKB/Swiss-Prot, http://www.
uniprot.org/) and the N-terminal region of FoxO3A
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(corresponding to positions 1–148) was performed. MPP
and MIP consensus motif-like peptide probes were used
to search exact matches in the N-terminal region of
FoxO3A (corresponding to positions 1–148).
Colony formation assay
Colony formation assays were performed as previously
described34. Briefly, cells were cultured in 60mm dishes in
the presence or absence of indicated drugs. After 24 h,
media were discarded and cells were washed twice with
1× PBS. An aliquot of 2 ml of Coomassie brilliant blue
(#161-0400, BIORAD) were added into each dish for 5
min and then cells were washed with ethanol 70% to
remove the excess of Coomassie. Plates were dried at
room temperature. Percent cell growth inhibition at each
concentration was quantified by densitometric evaluation
using ImageJ software.
Mitochondrial membrane potential assay (TMRE staining)
and immunofluorescence
Mitochondrial membrane potential assay was per-
formed using tetramethylrhodamine ethyl ester per-
chlorate (TMRE) (#87917, Sigma), according to the
manufacturer’s instructions. Nuclei were counterstained
using DAPI (#D1306, Invitrogen). HCT116-FoxO3A−/−
cells were transiently transfected with eGFP-tagged
mammalian expression plasmids (auto-fluorescence).
After transfection and treatment, cells were fixed with 4%
paraformaldehyde, permeabilized with 1% Triton X-100,
and then stained as described above. Images were
acquired using an Axio Observer Z1 microscope (Zeiss,
Jena, Germany) and quantification of mitochondrial
TMRE fluorescence in GFP+ cells was performed using
ZEN imaging software (Zeiss).
CRISPR/Cas9 system
The CRISPR/Cas9 reporter vector (GeneArt CRISPR
Nuclease Vector Kit, #A21175, Invitrogen) was used
according to the manufacturer’s instructions. HCT116
cells were transfected using Lipofectamine 3000
(#L3000015, Thermo Fisher Scientific) according to the
manufacturer’s instruction. Isolation of clonal populations
was performed with agarose-based cloning rings (#C1059,
Sigma). Cell clones were tested for site-specific deletions
by PCR. Sequencing products were purified using the Dye
Ex 2.0 Spin Kit (#63204, QIAGEN, Germantown, MD)
and sequenced on an ABI PRISM 310 Genetic Analyzer
(Applied Biosystems).
Oligonucleotide sequences used in this study to create
the gRNA vector:
gRNA top strand oligo: GTCTTCATCGTCCTCC
TCCT
gRNA bottom strand oligo: AGGAGGAGGACGAT
GAAGAC
Glucose restriction resistance assay
Glucose restriction resistance assays were performed on
several cell lines. For each of them, a preliminary
experiment was performed to determine the glucose
restriction end point. Total of 2.5× 104 cells were plated
for each cell line on a 12-well dish and switched 24 h later
to low glucose medium (0.75 mM glucose). Every 24 h, the
supernatants (containing dead/floating cells) were col-
lected, and the remaining adherent cells were detached by
Trypsin/EDTA (Sigma). Cell pellets were resuspended in
1× PBS and 10 μl were mixed with an equal volume of
0.01% trypan blue solution. Viable cells (unstained, trypan
blue negative cells) and dead cells (stained, trypan blue
positive cells) were counted with a phase contrast
microscope. For each cell line, the glucose restriction end
point was established as the time point in which the
amount of dead cells was at least 50% of the total. To
investigate the correlation between glucose restriction
resistance and FoxO3A protein levels, 2× 105 cells were
plated on 60-mm dishes and switched 24 h later to low
glucose medium (0.75 mM glucose). For each cell line,
cells were collected at the glucose restriction end point
preliminarily established as described above. Then, cell
pellets were lysed and total proteins were analyzed by
immunoblot with a FoxO3A antibody (CST). Densito-
metric evaluation of FoxO3A protein levels was per-
formed by ImageJ software. The correlation index
between cell resistance (days) and FoxO3A protein levels
was calculated as:
correl X;Yð Þ ¼
P
x xmð Þ  y ymð Þ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
P
x xmð Þ2
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiP
y ymð Þ2
qr
Statistical analysis
Results are expressed as mean± SEM and n ≥ 3. Stu-
dent’s t test was used to define p values. A *p< 0.05, **p<
0.01, and ***p< 0.001 were considered statistically sig-
nificant. Multiple comparisons are accounted for via the
Hochberg’s method using PROC MULTTEST in SAS, as
previously described20.
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